To Explore the Efficacy and Safety of Camrelizumab Combined With SHR1020 in the Treatment of Advanced Melanoma
Clinical trial NCT05051865 · UNKNOWN
Trial details
- NCT number
- NCT05051865
- Sponsor
- Peking University Cancer Hospital & Institute
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-10-09
- Primary completion
- 2024-08-30
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.